 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Biomarin Pharmaceuticals
BMRN
conference date: April 25, 2019 @ 1:30 PM Pacific Time
I will no longer be covering Biomarin, starting with Q1 2019.
FDA Approves BioMarin's Palynziq for PKU [FDA, 5/24/2018]
Pharmacyclics, BioMarin, And Incyte: A Quick Screen [Seeking Alpha, 3/26/2015]
2019 |
|||
Feb. 21, 2019 |
|||
2018 |
|||
Not Available Q3 2018 |
|||
Feb. 22, 2018 |
April 25, 2018 |
August 2, 2018 |
Oct. 25 2018 |
2017 |
|||
Feb. 23, 2017 |
May 4, 2017 |
August 2, 2017 |
Oct. 26, 2017 |
2016 |
|||
Biomarin Q3 not covered |
|||
02/25/2016 |
04/28/2016 |
08/04/2016 |
10/27/2016 |
Biomarin Pharmaceuticals (BRMN) is commercial stage biotechnology company specializing in therapies for rare disorders (orphan drugs).
Biomarin Pharmaceuticals web site
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| BIIB |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| ISRG |
| MCHP |
| MYL. |
| PLX |
| REGN |
| SGEN | TTPH |
| VBLT |
| VSTM |
| XLNX |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2016 William P. Meyers